DAFTAR PUSTAKA
1. Rea TH, Modlin RL. Leprosy. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editor. Fitzpatrick’s dermatology in general medicine. 8th ed. New York, McGraw-Hill. 2012. p.1786-96.
2. Bryceson A, Pfaltzgraff RE. Introduction. Mycobacterium leprae. Leprosy. 3th ed. New York: London Churchill Livingstone. 1990. p.1-10.
3. Amirudin MD, Hakim Z, Darwis E. Diagnostik Penyakit Kusta. In: Daili ESS, Menaldi SR, Ismiarto SP, Nilasari H, editor. Kusta. 2nd ed. Balai Penerbit FK UI. Jakarta. 2003. p.12-32.
4. Departemen Kesehatan RI Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Buku Pedoman Nasional Pemberantasan Penyakit Kusta. 2007. 18:1-75.
5. Infodatin. Pusat Data dan Informasi Kementrian Kesehatan RI. 2015. Available from: http://www.depkes.go.id [cited 2015 Nov 23rd].
6. Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia. Data dan Informasi Tahun 2014. 2015. Available from: http://www.depkes.go.id [cited 2015 Nov 23rd].
7. Phumla S. Drug Induced Hemolytic Anemia. Clinical pharmacology, 25, June, 2007. p.286-88.
8. Zhu YI, Stiller MJ. Dapson and Sulfones in Dermatology: Overview and Update. Journal American Academy of Dermatology. 2001; 45: 420-34. doi:10.1067/ mjd.2001.1147 33.
9. Bacman D, Kuhn A, Ruzicka T. Dapsone and Retinoids [internet]. In: Cutaneous Lupus Erythematosus, Part IV. 2005. Springer Berlin Heidelberg. doi:10.1007/3-540-26581-3_27.
10.Sago J, Hall RP. Dapsone. In: Tharp MD, editor. Dermatologic Therapy. Blackwell Publishing, Inc. 2002; 15: 340-51. doi: 10.1046/j.1529-8019.2002. 01543.
11.Coleman MD. Dapsone: Modes of Action, Toxicity and Possible Strategies for Increasing Patient Tolerance. British Journal of Dermatology. 1993; 129: 507-13.
12.Beutler E. Destruction of erythrocytes. In: Kaushansky K, Litchman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT, editor. William Hematology. 8th ed. McGraw-Hill, 2010. Chapter 32.
13.Oehadian A. Pendekatan klinis dan diagnosis anemia. CKD-194, 2012;39(6): 407-12.
15.Al-sieni AI, Al-Layati WZ, Al-Abbasi FA. Temporal Adverse Effect in Leprosy Saudi Patients Receiving Multi Drug Therapy. Clinical and Experimental Pharmacology. 2013;4(1):1-4. doi:10.4172/2161-1459.1000141. 16.Deps P, Guerra P, Nasser S, Simon M. Hemolytic anemia in patients receiving
daily dapsone for the treatment of leprosy. Lepr Rev (2012) 83, 305-7.
17.Singh H, Nel B, Dey V, Tiwari P, Dulhani N. Adverse effect of multi drug therapy in leprosy, a two years’ experience (2006–2008) in tertiary health care in the tribal region of Chhattisgarh state (Bastar, Jagdalpur). Lepr Rev (2001) 82, 17-24. doi: 0305-7518/11/064053+08.
18.Souza VNB, Malaspina TSS, Campanelli AP, Ghidella C, Ura S, Nascimento DC, et al. Increased in hepcidin expression in multibacillary leprosy. Mem Inst Oswaldo Cruz, Rio de Janeiro, 2012; 107(Suppl.I): 183-189.
19.Cho SC, Park MC, Keam B, Choi JM, Cho Y, Hyun S, et al. DDS, 4,4’ -Diaminodiphenylsulfone, Extends Organismic Lifespan. PNAS. November 9, 2010; 107(45), 19326-31.
20.Pfaltzgraff RE, Ramu G. Clinical leprosy. In: Hasting RC, Opromolla DVA, editor. Leprosy, 2nd ed. London: Churchill livingstone; 1994. p.237-85.
21.Lockwood DNJ. Leprosy. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 8th ed. United Kingdom: Wiley-blackwell. 2010. p.29.1-21.
22.Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL. The Continuing Challenges of Leprosy. Clin Microbiol Rev. 2006;19(2):338-81.
23.Robbins G. Ancient Skeletal Evidence for Leprosy in India (2000 BC). In: Petraglia M, editor. University of Cambridge, 2009. p.27:1-8.
24.Rachmat H. Program Pemberantasan Penyakit Kusta di Indonesia. In: Daili ESS, Menaldi SR, Ismiarto SP, Nilasari H, editor. Kusta. 2nd ed. Balai Penerbit FK UI. Jakarta. 2003. p.1-11.
25.World Health Organization. Leprosy today. 2014. Available from: http:www.who.int/lep/en [cited 2014 Des 1th].
26.Venkatesan K, Deo N. Biochemical Aspects. In: Hementa Kumark, Bhushan Kumar, et al. IAL Text Book of Leprosy, Jatpee Brothers Medical Publishers: New Delhi. 2010. p.87-99.
27.Bhat RM, Prakash C. Leprosy: An Overview of Pathophysiology. Hindawi Publishing Corporation Interdisciplinary Perspectives on Infectious Disease, 2012; 1-5.
28.Goncalves A, Mantellini GG, Padovani CR. Leprosy Control: Perspective and Epidemiological and Operational Aspects. Rev. Inst. Med. Trop. Sao Paulo. 2010; 52(6):311-5.
29.Bizuneh E. Leprosy. International Neuroinfectious Diseases Conference. 2010;1-59.
31.Sengupta. Immunology of Leprosy, a State of The Art. Internasional Journal of Leprosy and Other Mycobacterial Disease. June 2001:69,2.
32.Nath I, Saini C, Valluri VL. Immunology of Leprosy and Diagnostic Challenges. Clinics in Dermatology. 2015; 33: 90-8.
33.Bryceson A, Pfaltzgraff RE. Symptom and sign. Leprosy. 3rd ed. New York: London Churchill Livingstone; 1990. p.25-56.
34.Bryceson A, Pfaltzgraff RE. Diagnosis. Leprosy. 3rd ed. New York: London Churchill Livingstone; 1990. p.57-76.
35.Mishra RS, Kumar J. Classification. In: Hementa Kumark, Bhushan Kumar, et al. IAL Text Book of Leprosy, Jatpee Brothers Medical Publishers: New Delhi. 2010. p.144-51.
36.Soebono H, Bambang S. Pengobatan penyakit kusta. In: Daili ESS, Menaldi SR, Ismiarto SP, Nilasari H, editor. Kusta. 2nd edition. Balai Penerbit FK UI. Jakarta. 2003. p.66-74.
37.Manglani PR, Ma A. Multidrug therapy in leprosy. Journal of Indian Medical Association. 2006; 19:338-81.
38.Joni G. Sago R. Dapsone. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editor. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012 p. 4366-76.
39.Jollow DJ, Bradshaw TP, McMillan DC. Dapson-Induced Hemolytic Anemia. Departement of Cell and Molecular Pharmacology and Experimental Theurapeutics Medical University of South Carolina, 1995. Available from: http://www.informahealthcare.com
40.Quieroz RHC, Melchior E, Souza AM, Gouveia E, Barbosa JC, Carvalho D. Haematological and Biochemical Alterations in Leprosy Patients Already Treated with Dapsone and MDT. Pharmaceutica Acta Helvetiae. 1997; 72: 209-13.
41.Halim NKD, Ogbeide E. Haematological Alterations in Leprosy Patients Treated with Dapsone. East Africa Medical Journal. 2002; 79(2): 100-2. 42.Perkins S. Diagnosis of Anemia. In: Kjeldsberg CR, Perkins SL, Anastasi J,
Arber DA, Bahler DW, Blaylock RC, et al. Editor: Practical Diagnosis of Hematologic Disorder. American Society for Clinical Pathology. 2010.p.3-15. 43.Tolentino K, Friedman JF. An Update on Anemia in Less Developed
Countries. Am J Trop Med Hyg. 77(1), 2007, p.44-51.
44.World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Department of Nutrition for Health and Development.2011. Available from: http:www.who.int/ lep/en. [cited 2016 Jan 14th].
46.Muller A, Jacobsen H, Healy E, McMickan S, Istace F, Blaude MN, et al. Hazard classification of chemicals inducing haemolytic anaemia: An EU regulatory perspective. Regulatory Toxicology and Pharmacology. August 2006; 45(3):229-241.
47.Prchal JT. Production of erythrocyte. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT. Williams Hematology. 8th edition. Mc Graw Hill. 2010. Chap.32.
48.Adamson JW, Longo L. Anemia and Polycythemia. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editor. Harrison’s Principles of Internal Medicine. 18th edition. Mc Graw Hill. 2012. p.448-56.
49.Scheelbeck PFD, Balagon MVF, Orcullo FM, Maghanoy AA, Abellana J, Saunderson PR. A Retrospective Study of The Epidemiology of Leprosy in Cebu: An Eleven-Year Profile. Plos Neglected Tropical Diseases. 2013 September; 7(9):e2444. p.1-12. doi: 10.1371/journal.pntd.000.2444.
50.Tosepu R, Effendy DS, Imran LOA, Asfian P. Epidemiology study of leprosy patients in the district of Bombana Southeast Sulawesi Province, Indonesia. Int J Res Med Sci. 2015 May; 3(5): 1262-1265. doi: 10.5455/2320-6012.ijrms20150541.
51.Ramos JM, Martin MM, Reyes F, Lemma D, Belinchon I, Gutierrez F. Gender differential on charactheristics and outcome of leprosy patients admitted to a long-term care rural hospital in South-Eastern Ethiopia. International Journal
for Equity in Health. 2012; 11(56):1-7.
http://www.equityhealthj.com/content/11/1/56.
52.Kumar RBC, Singhasivanon P, Sherchand JB, Mahaisavariya P, Kaewkungwal J, Peerapakorn S, et al. Gender differences in epidemiological factors associated with treatment completion status of leprosy patients in the most hyperendemic district of Nepal. Southeast Asian J Trop Med Public Health. 2004 June; 35(2):334-339.
53.Thorat DM, Sharma P. Epidemiology. In: Kar HK, Kumar B. IAL Textbook of Leprosy. 1st ed. New Delhi: JPBMP; 2010. p.24-31.
54.Lastoria JC, Abreu MAMM. Leprosy: review of epidemiological, clinical and ethiopathogenic aspects – part 1. An Bras Dermatol. 2014; 8(9)2:205-18. doi: http://dx.doi.org/10.1590/abd1806-4841.20142450.
55.Fajar A, Lubis SR. Pengukuran kadar antibodi PGL-1 penderita kusta (studi banding antara sampel darah finger prick dengan menggunakan kertas saring dan sampel serum darah tanpa kertas saring). Repository USU. 2012:1-15. 56.Varkevisser CM, Lever P, Alubo O, Burathoki K, Idawani C, Moreira TMA.
Gender and leprosy: case studies in Indonesia, Nigeria, Nepal and Brazil. Lepr rev. 2009; 80:65-76.
most hyperendemic district of Nepal. Southeast Asian J Trop Med Public Health. June, 2004;35(2):334-339.
58.Guillaud C, Loustau V, Michel M. hemolytic anemia in adults: main causes and diagnostic procedures. Expert Rev Hematol. 5(2), 2012: 229-41. doi: http://dx.doi.org/10.1586/ehm.12.3
